Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.

Journal of managed care & specialty pharmacy·2022
Same author

Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.

The Journal of family practice·2021
Same author

Diabetes Management Update: Individualizing Treatment.

The Journal of family practice·2019
Same author

Improved glycaemic control and lower hypoglycaemia risk with reduced prior oral antidiabetes drug therapy in patients with type 2 diabetes treated with insulin glargine 300 U/mL.

Endocrinology, diabetes & metabolism·2019
Same author

Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables.

Clinical therapeutics·2019
Same author

Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes.

BMJ open diabetes research & care·2019

Related Experiment Video

Updated: Sep 1, 2025

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K

Practical Screening for Islet Autoantibodies: The Time Has Come.

Timothy Reid1

  • 1Timothy Reid, MD, Mercyhealth Diabetes Center, Janesville, Wisconsin.

The Journal of Family Practice
|August 12, 2022
PubMed
Summary
This summary is machine-generated.

Family physicians can screen relatives of type 1 diabetes (T1D) patients for T1D autoantibodies. Early identification of at-risk individuals through screening offers significant health benefits and supports participation in prevention trials.

More Related Videos

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

2.6K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K

Related Experiment Videos

Last Updated: Sep 1, 2025

Electrochemiluminescence Assays for Human Islet Autoantibodies
09:15

Electrochemiluminescence Assays for Human Islet Autoantibodies

Published on: March 23, 2018

15.6K
A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases
06:50

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

2.6K
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K

Area of Science:

  • Endocrinology
  • Family Medicine
  • Genetics

Background:

  • Type 1 diabetes (T1D) prevalence is rising, increasing the likelihood of family physicians encountering first-degree relatives at genetic risk.
  • These relatives may possess a genetic predisposition for developing T1D.

Purpose of the Study:

  • To highlight the importance of T1D autoantibody screening by family clinicians.
  • To identify individuals at high risk for T1D early.
  • To underscore the short- and long-term health benefits of early detection.

Main Methods:

  • Discussing the availability of multiple T1D screening options and programs for clinicians.
  • Emphasizing comprehensive programs that include patient education, testing, result analysis, and follow-up.
  • Mentioning the opportunity for participants to engage in T1D prevention trials.

Main Results:

  • Family medicine clinicians are uniquely positioned to offer monitoring and follow-up.
  • Positive autoantibody results in family members necessitate crucial provider-patient relationship support.
  • Early screening facilitates timely intervention and management strategies.

Conclusions:

  • T1D autoantibody screening by family physicians is a vital tool for early risk identification.
  • Leveraging the provider-patient relationship in family medicine is key for effective monitoring and follow-up of at-risk individuals.
  • Screening programs support proactive health management and potential participation in T1D prevention research.